



Peer-Reviewed Article on Ortho RTi's Ortho-R Implants to Promote Tissue Regeneration Published in
Journal of Tissue Engineering and Regenerative Medicine

Kirkland, QC, January 30, 2018 – Ortho Regenerative Technologies Inc. (CSE: **ORTH.CN**) (“**Ortho RTi**” or the “**Corporation**”), an emerging Orthopaedic and Sports Medicine Technology company, today announced that a peer-reviewed article entitled “[Ortho-R] Implants to Promote Tissue Regeneration: *In Vitro* Properties, *In Vivo* Residence, Degradation, Cell Recruitment and Vascularization” has been published in the current issue of *Journal of Tissue Engineering and Regenerative Medicine*. This journal is at the top 10% of all scientific journals for its impact and importance.

“This is our fourth peer-reviewed article in just the last few months. As such, we are very encouraged by the scientific validation of these publications and by the testing so far of Ortho-R implants in pre-clinical cartilage, meniscus and rotator cuff repair models. It is our expectation that repair outcomes will be significantly improved as compared to current clinical treatments,” said the Corporation’s Executive Chairman and CEO, Dr. Brent Norton.

The purpose of the study reported in the article was to identify freeze-dried chitosan formulations that can be solubilized in platelet-rich plasma (PRP) to form injectable gelling [Ortho-R] implants for tissue repair. Such a regenerative medicine system could overcome the previous shortcomings of solution-based chitosan systems as well as improve the regenerative capacity of PRP by physically stabilizing PRP *in vivo* through reinforcement with a degradable and biocompatible polymer. An abstract of the article can be accessed on the internet at http://www.orthorti.com/cms_files/php3VQoG.pdf.

Quoting directly from the article, “In summary, freeze-dried chitosan formulations can be solubilized in PRP to form injectable coagulating biodegradable and biocompatible implants for tissue repair applications. The properties of the [Ortho-R] implants can be modulated by selecting the chitosan molar mass (*M_n*), chitosan concentration and lyoprotectant concentration in the freeze-dried cakes. Unlike PRP alone, these [Ortho-R] implants are physically stable and persist *in vivo* so that they are expected to significantly prolong bioactivity for tissue repair. Future indications for [Ortho-R] implants include meniscus repair, cartilage repair and rotator cuff repair.”

Journal of Tissue Engineering and Regenerative Medicine publishes rapidly and rigorously peer-reviewed research papers, reviews, clinical case reports, perspectives, and short communications on topics relevant to the development of therapeutic approaches which combine stem or progenitor cells, biomaterials and scaffolds, growth factors and other bioactive agents, and their respective constructs.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. We are committed to improving patients’ lives through increasing the



success rates of surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further Information, please contact:

Stephen Kilmer

Investor & Media Relations

647.872.4849

kilmer@orthorti.com